-
Product Insights
NewNet Present Value Model: Tyra Biosciences Inc’s TYRA-300
Empower your strategies with our Net Present Value Model: Tyra Biosciences Inc's TYRA-300 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Tyra Biosciences Inc’s TYRA-200
Empower your strategies with our Net Present Value Model: Tyra Biosciences Inc's TYRA-200 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TYRA-200 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TYRA-200 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TYRA-200 in Solid Tumor Drug Details: TYRA-200 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TYRA-200 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TYRA-200 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TYRA-200 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: TYRA-200 is...
-
Product Insights
Tyra Field
Tyra Field is a producing field located in North Sea, Denmark. It is being operated by Total E&P Denmark AS. Empower your strategies with our Tyra Field report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance....
-
Product Insights
Tyra SE Field
Tyra SE Field is a producing field located in North Sea, Denmark. It is being operated by Total E&P Denmark AS. Empower your strategies with our Tyra SE Field report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Follicular Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Follicular Thyroid Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Follicular Thyroid Cancer Drug Details: Cabozantinib s-malate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linvoseltamab in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linvoseltamab in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linvoseltamab in Refractory Multiple Myeloma Drug Details: Linvoseltamab (REGN-5458) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lemzoparlimab in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in Epithelial Ovarian Cancer Drug Details: TJC-4 (lemzoparlimab) is...
-
Product Insights
Achondroplasia – Drugs In Development, 2023
Global Markets Direct’s, ‘Achondroplasia - Drugs In Development, 2023’, provides an overview of the Achondroplasia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Achondroplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...